Publication:
Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice

Issued Date

2020-01-01

Resource Type

Review

ISSN

25868470
25868195

DOI

10.29090/psa.2020.02.019.0095

Other identifier(s)

2-s2.0-85085209446

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Pharmaceutical Sciences Asia. Vol.47, No.2 (2020), 104-112

Suggested Citation

Jennis Meanwatthana Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice. Pharmaceutical Sciences Asia. Vol.47, No.2 (2020), 104-112. doi:10.29090/psa.2020.02.019.0095 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/56284

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice

Author(s)

Jennis Meanwatthana

Other Contributor(s)

Mahidol University

Abstract

© Faculty of Pharmacy, Mahidol University (Thailand) 2020. Immune checkpoint inhibitors (ICIs) have significantly driven the oncology treatment landscape as they immensely shift better clinical outcomes among various type of cancers. Challenges of using this approach are, without doubt, the immune related adverse events (IrAEs). These can have vital impact to affect multiple organs and some cases lead to fatality. Therefore, risk stratification should be cautiously taken into consideration while clinicians are dealing with ICIs. In this article, the risk factors from clinical trials or real-world reports that relevant to onset, level of severity, and particular type of IrAEs were discussed in order to promote IrAEs prompt attention in clinical practice.

Keyword(s)

Medicine
 Pharmacology, Toxicology and Pharmaceutics

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/56284

Collections

Scopus 2020